Nothing Special   »   [go: up one dir, main page]

WO2002060474A3 - Gemische von enzymen aus pilzen und deren verwendung zur behandlung der maldigestion - Google Patents

Gemische von enzymen aus pilzen und deren verwendung zur behandlung der maldigestion Download PDF

Info

Publication number
WO2002060474A3
WO2002060474A3 PCT/EP2002/000374 EP0200374W WO02060474A3 WO 2002060474 A3 WO2002060474 A3 WO 2002060474A3 EP 0200374 W EP0200374 W EP 0200374W WO 02060474 A3 WO02060474 A3 WO 02060474A3
Authority
WO
WIPO (PCT)
Prior art keywords
maldigestion
mixtures
treating
pharmaceutical preparations
enzymes
Prior art date
Application number
PCT/EP2002/000374
Other languages
English (en)
French (fr)
Other versions
WO2002060474A2 (de
Inventor
Manfred Galle
Peter-Colin Gregory
Andreas Potthoff
Friederike Henniges
Original Assignee
Solvay Pharm Gmbh
Manfred Galle
Peter-Colin Gregory
Andreas Potthoff
Friederike Henniges
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE10144711A external-priority patent/DE10144711A1/de
Priority to HU0500560A priority Critical patent/HUP0500560A3/hu
Priority to EP02716661A priority patent/EP1381386A2/de
Priority to PL02362646A priority patent/PL362646A1/xx
Priority to KR10-2003-7009470A priority patent/KR20030067752A/ko
Priority to BR0206521-5A priority patent/BR0206521A/pt
Priority to SK929-2003A priority patent/SK9292003A3/sk
Priority to JP2002560665A priority patent/JP2004524838A/ja
Application filed by Solvay Pharm Gmbh, Manfred Galle, Peter-Colin Gregory, Andreas Potthoff, Friederike Henniges filed Critical Solvay Pharm Gmbh
Priority to IL15700402A priority patent/IL157004A0/xx
Priority to NZ527148A priority patent/NZ527148A/en
Priority to CA002434808A priority patent/CA2434808A1/en
Priority to MXPA03005960A priority patent/MXPA03005960A/es
Publication of WO2002060474A2 publication Critical patent/WO2002060474A2/de
Priority to US10/620,759 priority patent/US20040057944A1/en
Priority to NO20033261A priority patent/NO20033261L/no
Publication of WO2002060474A3 publication Critical patent/WO2002060474A3/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Es werden neue Gemische mikrobieller Enzyme beschrieben, welche eine konzentrierte Lipase von Rhizopus delemar und zusätzlich eine Protease von Aspergillus melleus sowie eine Amylase von Aspergillus oryzae enthalten. Weiterhin werden diese Gemische mikrobieller Enzyme enthaltende pharmazeutische Zubereitungen beschrieben. Die neuen pharmazeutischen Zubereitungen sind besonders gut geeignet zur Behandlung und/oder Prophylaxe der Maldigestion, insbesondere der auf Pankreasinsuffizienz beruhenden Maldigestion, in Säugetieren und Menschen.
PCT/EP2002/000374 2001-01-19 2002-01-16 Gemische von enzymen aus pilzen und deren verwendung zur behandlung der maldigestion WO2002060474A2 (de)

Priority Applications (13)

Application Number Priority Date Filing Date Title
MXPA03005960A MXPA03005960A (es) 2001-01-19 2002-01-16 Nuevas mezclas de enzimas microbianas.
JP2002560665A JP2004524838A (ja) 2001-01-19 2002-01-16 微生物酵素の新規混合物
PL02362646A PL362646A1 (en) 2001-01-19 2002-01-16 Novel mixtures of microbial enzymes
KR10-2003-7009470A KR20030067752A (ko) 2001-01-19 2002-01-16 미생물 효소의 신규 혼합물
IL15700402A IL157004A0 (en) 2001-01-19 2002-01-16 Novel mixtures of microbial enzymes
SK929-2003A SK9292003A3 (en) 2001-01-19 2002-01-16 Novel mixtures of microbial enzymes
EP02716661A EP1381386A2 (de) 2001-01-19 2002-01-16 Gemische von enzymen aus pilzen und deren verwendung zur behandlung der maldigestion
HU0500560A HUP0500560A3 (en) 2001-01-19 2002-01-16 Mixtures of mushroom enzymes and the use thereof for treating maldigestion
BR0206521-5A BR0206521A (pt) 2001-01-19 2002-01-16 Misturas de enzimas microbianas
NZ527148A NZ527148A (en) 2001-01-19 2002-01-16 Novel mixtures of microbial enzymes
CA002434808A CA2434808A1 (en) 2001-01-19 2002-01-16 Novel mixtures of microbial enzymes
US10/620,759 US20040057944A1 (en) 2001-01-19 2003-07-17 Microbial enzyme mixtures useful to treat digestive disorders
NO20033261A NO20033261L (no) 2001-01-19 2003-07-18 Nye blandinger av mikrobielle enzymer

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE10102495 2001-01-19
DE10102495.9 2001-01-19
DE10144711A DE10144711A1 (de) 2001-01-19 2001-09-11 Neue Gemische mikrobieller Enzyme
DE10144711.6 2001-09-11

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US10/620,759 Continuation US20040057944A1 (en) 2001-01-19 2003-07-17 Microbial enzyme mixtures useful to treat digestive disorders

Publications (2)

Publication Number Publication Date
WO2002060474A2 WO2002060474A2 (de) 2002-08-08
WO2002060474A3 true WO2002060474A3 (de) 2003-10-30

Family

ID=26008287

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2002/000374 WO2002060474A2 (de) 2001-01-19 2002-01-16 Gemische von enzymen aus pilzen und deren verwendung zur behandlung der maldigestion

Country Status (17)

Country Link
US (1) US20040057944A1 (de)
EP (1) EP1381386A2 (de)
JP (1) JP2004524838A (de)
CN (1) CN1236817C (de)
AR (1) AR032392A1 (de)
BR (1) BR0206521A (de)
CA (1) CA2434808A1 (de)
CZ (1) CZ20031900A3 (de)
HU (1) HUP0500560A3 (de)
IL (1) IL157004A0 (de)
MX (1) MXPA03005960A (de)
NO (1) NO20033261L (de)
NZ (1) NZ527148A (de)
PL (1) PL362646A1 (de)
RU (1) RU2003124078A (de)
SK (1) SK9292003A3 (de)
WO (1) WO2002060474A2 (de)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6632429B1 (en) 1999-12-17 2003-10-14 Joan M. Fallon Methods for treating pervasive development disorders
US20010046493A1 (en) * 2000-02-24 2001-11-29 Alex Margolin Lipase-containing composition and methods of use thereof
US20070053895A1 (en) 2000-08-14 2007-03-08 Fallon Joan M Method of treating and diagnosing parkinsons disease and related dysautonomic disorders
IT1319655B1 (it) 2000-11-15 2003-10-23 Eurand Int Microsfere di enzimi pancreatici con elevata stabilita' e relativometodo di preparazione.
US8030002B2 (en) 2000-11-16 2011-10-04 Curemark Llc Methods for diagnosing pervasive development disorders, dysautonomia and other neurological conditions
US8100844B2 (en) * 2002-04-25 2012-01-24 Ultraflex Systems, Inc. Ambulating ankle and knee joints with bidirectional dampening and assistance using elastomeric restraint
AU2004285558A1 (en) * 2003-10-29 2005-05-12 Altus Pharmaceuticals Inc. Non-pancreatic proteases for controlling plasma cholecystokinin (CCK) concentration and for treating pain
DE602005009677D1 (de) 2004-03-22 2008-10-23 Solvay Pharm Gmbh Orale pharmazeutische zusammensetzungen von produkten mit lipase, insbesondere von pankreatin, mit tensiden
CA2586222A1 (en) * 2004-05-24 2005-12-08 Novozymes A/S Enzymes for pharmaceutical use
US20060198838A1 (en) * 2004-09-28 2006-09-07 Fallon Joan M Combination enzyme for cystic fibrosis
WO2006044529A1 (en) * 2004-10-14 2006-04-27 Altus Pharmaceuticals Inc. Compositions containing lipase; protease and amylase for treating pancreatic insufficiency
EP1896058A2 (de) * 2005-06-24 2008-03-12 Novozymes A/S Proteasen zur pharmazeutischen verwendung
US8017351B2 (en) * 2005-06-24 2011-09-13 Novozymes A/S Amylases for pharmaceutical use
AU2006261442A1 (en) * 2005-06-24 2006-12-28 Novozymes A/S Lipases for pharmaceutical use
WO2007014896A1 (en) 2005-07-29 2007-02-08 Solvay Pharmaceuticals Gmbh Processes for the manufacture of sterilized pancreatin powder
US9198871B2 (en) 2005-08-15 2015-12-01 Abbott Products Gmbh Delayed release pancreatin compositions
US11266607B2 (en) 2005-08-15 2022-03-08 AbbVie Pharmaceuticals GmbH Process for the manufacture and use of pancreatin micropellet cores
MX2008001557A (es) * 2005-08-15 2008-02-15 Solvay Pharm Gmbh Nucleos de microglobulos de pancreativa adecuados para revestimiento enterico.
US20080058282A1 (en) 2005-08-30 2008-03-06 Fallon Joan M Use of lactulose in the treatment of autism
US20070116695A1 (en) * 2005-09-21 2007-05-24 Fallon Joan M Pharmaceutical preparations for attention deficit disorder, attention deficit hyperactivity disorder and other associated disorders
US20100196344A1 (en) * 2005-10-14 2010-08-05 Cystic Fibrosis Foundation Therapeutics, Inc. Compositions and methods for treating pancreatic insufficiency
US8071089B2 (en) * 2005-11-01 2011-12-06 Bio-Cat, Inc. Composition with a fungal (yeast) lipase and method for treating lipid malabsorption in cystic fibrosis as well as people suffering from pancreatic lipase insufficiency
US10072256B2 (en) 2006-05-22 2018-09-11 Abbott Products Gmbh Process for separating and determining the viral load in a pancreatin sample
US20080081035A1 (en) * 2006-10-03 2008-04-03 National Enzyme Company Therapeutic protease compositions
JP2010510310A (ja) 2006-11-22 2010-04-02 スタンダード バイオロジックス インコーポレイテッド コウジカビプロテアーゼを使用する処置の方法
KR20090101930A (ko) 2006-12-21 2009-09-29 노보자임스 에이/에스 약학적 사용을 위한 리파아제 변형체
US20080199448A1 (en) * 2007-02-16 2008-08-21 Ross Mairi R Enzyme composition for improving food digestion
ES2560527T3 (es) 2007-02-20 2016-02-19 Allergan Pharmaceuticals International Limited Composiciones estables de enzimas digestivas
US20090068174A1 (en) * 2007-09-12 2009-03-12 Kansas University Medical Center Research Institute, Inc. Therapeutic alkaline protease compositions and use in facilitating the transport of agents across the gastrointestinal mucosal lining
US20090130063A1 (en) * 2007-11-15 2009-05-21 Solvay Pharmaceuticals Gmbh Process for separating and determining the viral load in a pancreatin sample
CA2707658A1 (en) 2007-12-04 2009-06-11 Novozymes A/S Protease variants for pharmaceutical use
AU2009203123A1 (en) * 2008-01-03 2009-07-09 Abbott Products Gmbh Pharmaceutical compositions comprising granules of purified microbial lipase and methods of preventing or treating digestive disorders
WO2009109856A2 (en) 2008-03-07 2009-09-11 Axcan Pharma Inc. Method for detecting infectious parvovirus in pharmaceutical preparations
US8658163B2 (en) 2008-03-13 2014-02-25 Curemark Llc Compositions and use thereof for treating symptoms of preeclampsia
US8084025B2 (en) 2008-04-18 2011-12-27 Curemark Llc Method for the treatment of the symptoms of drug and alcohol addiction
US20090324730A1 (en) * 2008-06-26 2009-12-31 Fallon Joan M Methods and compositions for the treatment of symptoms of complex regional pain syndrome
US9320780B2 (en) * 2008-06-26 2016-04-26 Curemark Llc Methods and compositions for the treatment of symptoms of Williams Syndrome
WO2010002972A1 (en) * 2008-07-01 2010-01-07 Curemark, Llc Methods and compositions for the treatment of symptoms of neurological and mental health disorders
US10776453B2 (en) * 2008-08-04 2020-09-15 Galenagen, Llc Systems and methods employing remote data gathering and monitoring for diagnosing, staging, and treatment of Parkinsons disease, movement and neurological disorders, and chronic pain
WO2010037695A1 (en) * 2008-09-30 2010-04-08 Dsm Ip Assets B.V. Enzyme composition and application thereof in the treatment of pancreatic insufficiency
US20100092447A1 (en) 2008-10-03 2010-04-15 Fallon Joan M Methods and compositions for the treatment of symptoms of prion diseases
ES2668909T3 (es) 2009-01-06 2018-05-23 Galenagen, Llc Composiciones que comprenden proteasa, amilasa y lipasa para su uso en el tratamiento de infecciones por Staphylococcus aureus
AU2015252099B2 (en) * 2009-01-06 2017-08-10 Galenagen, Llc Compositions and methods for the treatment or prevention of staphylococcus aureus infections and for the eradication or reduction of staphylococcus aureus on surfaces
NZ593823A (en) 2009-01-06 2013-09-27 Curelon Llc Compositions and methods for the treatment or the prevention of infections by e. coli
US9056050B2 (en) 2009-04-13 2015-06-16 Curemark Llc Enzyme delivery systems and methods of preparation and use
US9511125B2 (en) 2009-10-21 2016-12-06 Curemark Llc Methods and compositions for the treatment of influenza
AU2011228743A1 (en) * 2010-03-19 2012-10-11 Aptalis Pharma Canada, Inc. Gastro-resistant enzyme pharmaceutical compositions
AR093181A1 (es) 2010-10-01 2015-05-27 Aptalis Pharmatech Inc Formulacion con contenido de enzimas digestivas bajo estable
DK2654567T3 (en) 2010-12-22 2018-06-25 Novozymes North America Inc Process for making fermentation products from starch-containing materials
MX347770B (es) 2011-04-21 2017-05-12 Curemark Llc Compuesto para el tratamiento de alteraciones neuropsiquiatricas.
DK2741766T3 (en) 2011-08-08 2016-01-11 Aptalis Pharma Ltd Process for dissolving solid compositions containing digestive enzymes
CN104245942A (zh) * 2011-12-02 2014-12-24 诺维信公司 用于制造发酵产物的方法
US10350278B2 (en) 2012-05-30 2019-07-16 Curemark, Llc Methods of treating Celiac disease
AU2013318686B2 (en) 2012-09-19 2017-11-30 Grespo Ab Compositions for improvement of brain function
BR112015023278A2 (pt) 2013-03-15 2019-08-27 Allergan Pharmaceuticals International Limited processo para preparação de uma composição líquida estável e homogênea; composição líquida estável e homogênea; e método de administração de uma composição
US11939552B2 (en) 2013-06-24 2024-03-26 Novozymes A/S Process of recovering oil
HUE057274T2 (hu) 2013-06-24 2022-04-28 Novozymes As Eljárás olaj kinyerésére fermentációs termék elõállítására szolgáló eljárásokból és eljárások fermentációs termékek elõállítására
WO2015019198A2 (en) * 2013-07-22 2015-02-12 Aptalis Pharma S.R.L. High potency pancreatin pharmaceutical compositions
EP3030257B1 (de) 2013-08-09 2020-02-19 Allergan Pharmaceuticals International Limited Verdauungsenzymzusammensetzung zur enteralen verabreichung
RU2015155470A (ru) 2013-11-05 2017-08-21 Апталис Фарма Лтд. Высокоэффективные фармацевтические композиции панкреатина
MX2016016907A (es) 2014-06-19 2018-04-26 Aptalis Pharma Ltd Metodo para eliminar contaminantes virales de extractos pancreaticos.
GB201501081D0 (en) 2015-01-22 2015-03-11 Cilian Ag Use of enzymes with a wide pH activity range as medicaments for promoting digestion
US20180028454A1 (en) * 2015-02-04 2018-02-01 Abbvie Inc. Pharmaceutical compositions and methods of use thereof to treat pancreatic enzyme insufficiency
WO2019060851A1 (en) * 2017-09-24 2019-03-28 Bio-Cat, Inc. MIXTURES OF FUNGAL PROTEASE AND USES THEREOF
FR3079146B1 (fr) 2018-03-23 2020-04-17 Karim Ioualalen Formulation gastroprotectrice de complexes d’enzymes permettant de restaurer la fonction digestive.
FR3111559A1 (fr) * 2020-06-18 2021-12-24 Azurrx Biopharma, Inc. Formulations non porcines et leurs procédés
US11541009B2 (en) 2020-09-10 2023-01-03 Curemark, Llc Methods of prophylaxis of coronavirus infection and treatment of coronaviruses

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1084431A (en) * 1964-05-06 1967-09-20 Analyses Et De Rech S Biolog M Improvements in and relating to lipases
DE2638088A1 (de) * 1976-08-24 1978-03-02 Degussa Verfahren zur herstellung von verbesserten arzneizubereitungen, die lipase nicht-tierischen ursprungs enthalten
JPH04370096A (ja) * 1991-06-14 1992-12-22 Amano Pharmaceut Co Ltd 微生物起源リパーゼの安定化組成物及び安定化法
DE4332985A1 (de) * 1993-09-28 1995-03-30 Konrad Peter Maria Dr Sommer Arzneimittel zur Behandlung der Dysfunktion des exokrinen Pankreas

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5750104A (en) * 1996-05-29 1998-05-12 Digestive Care Inc. High buffer-containing enteric coating digestive enzyme bile acid compositions and method of treating digestive disorders therewith
US6013680A (en) * 1997-10-21 2000-01-11 Amano Pharmaceutical Co., Ltd. Digestive enzyme-containing medicament

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1084431A (en) * 1964-05-06 1967-09-20 Analyses Et De Rech S Biolog M Improvements in and relating to lipases
DE2638088A1 (de) * 1976-08-24 1978-03-02 Degussa Verfahren zur herstellung von verbesserten arzneizubereitungen, die lipase nicht-tierischen ursprungs enthalten
JPH04370096A (ja) * 1991-06-14 1992-12-22 Amano Pharmaceut Co Ltd 微生物起源リパーゼの安定化組成物及び安定化法
DE4332985A1 (de) * 1993-09-28 1995-03-30 Konrad Peter Maria Dr Sommer Arzneimittel zur Behandlung der Dysfunktion des exokrinen Pankreas

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Section Ch Week 9305, Derwent World Patents Index; Class B04, AN 1993-042580, XP002232576 *

Also Published As

Publication number Publication date
MXPA03005960A (es) 2003-09-05
PL362646A1 (en) 2004-11-02
HUP0500560A3 (en) 2006-06-28
NO20033261D0 (no) 2003-07-18
US20040057944A1 (en) 2004-03-25
HUP0500560A2 (hu) 2005-09-28
NO20033261L (no) 2003-07-18
EP1381386A2 (de) 2004-01-21
CA2434808A1 (en) 2002-08-08
IL157004A0 (en) 2004-02-08
CN1487837A (zh) 2004-04-07
BR0206521A (pt) 2004-02-17
NZ527148A (en) 2005-01-28
JP2004524838A (ja) 2004-08-19
AR032392A1 (es) 2003-11-05
CZ20031900A3 (cs) 2003-10-15
SK9292003A3 (en) 2003-12-02
RU2003124078A (ru) 2005-01-27
WO2002060474A2 (de) 2002-08-08
CN1236817C (zh) 2006-01-18

Similar Documents

Publication Publication Date Title
WO2002060474A3 (de) Gemische von enzymen aus pilzen und deren verwendung zur behandlung der maldigestion
NZ606504A (en) Modified proteases that inhibit complement activation
DK1162995T3 (da) Enzymer til behandling af diabetes mellitus type I
WO2008021987A3 (en) Proteolytic enzyme formulations
HK1101342A1 (en) Oral pharmaceutical compositions of lipase-containing products, in particular of pancreatin, containing surfactants
WO1994016073A3 (en) Methods and reagents for inhibiting furin endoprotease
DK1755656T3 (da) Enzymer til farmaceutisk anvendelse
WO2007053619A3 (en) A composition with a fungal (yeast) lipase and method for treating lipid malabsorption in cystic fibrous as well as people suffering from pancreatic lipase insufficiency
AU6328094A (en) Saccharin derivative proteolytic enzyme inhibitors
DK39093D0 (da) Enzym
DE3785036D1 (de) Verwendung katabolischer enzyme zur herstellung eines medikaments zum bekaempfen der erworbenen immunschwaeche (aids) und deren vorstadien (las, arc).
WO2006136160A3 (en) Proteases for pharmaceutical use
AU2002354696A1 (en) Method for purifying an enzyme, a purified enzyme produced thereby, and use of this enzyme
BR9301489A (pt) Processos para a preparacao de enzima purificada a partir de um caldo de fermentacao e para a preparacao de protease alcalina purificada derivada de bacillus alcalophilus ou bacillus lichenformis a partir de um caldo de fermentacao,uso de uma protease alcalina purificada e composicao solida e liquida
DE69333639D1 (en) Trypsininhibitoren
HUP0002644A2 (hu) Aldóz reduktáz inhibítort és ACE inhibitort tartalmazó gyógyászati készítmények
NZ337087A (en) C-terminal fragment of pancreatic lipase for hyperlipaemia, obesity, and cardiovascular disorders
AU3719100A (en) Inhibitors of serine protease activity, methods and compositions for treatment of viral infections
BR9809348A (pt) Inibidores de enzimas celulolìticas, xilanolìticas e b-glucanolìticas
ES2059666T3 (es) Utilizacion de enzimas catabolicas para el tratamiento de una infeccion vih.
ES2171136A1 (es) Enzima con actividad proteolitica construccion de adn que comprende una secuencia de adn que codifica dicha enzima y sus aplicaciones.
WO2004024765A8 (en) Crystal structure of an angiotensin-converting enzyme (ace) and uses thereof
RU2002120776A (ru) Способ профилактики рецидивов гнойного дакриоцистита после дакриоцисториностомии
EP1201679A3 (de) Angiotensinumwandelndes Enzym hemmende Verbindung
WO2000021547A3 (de) Beeinflussung von hyperaktiven t-zellen durch proteolytische enzyme

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 200304986

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: PA/a/2003/005960

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2002716661

Country of ref document: EP

Ref document number: PV2003-1900

Country of ref document: CZ

WWE Wipo information: entry into national phase

Ref document number: 2434808

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1020037009470

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 157004

Country of ref document: IL

Ref document number: 1-2003-500631

Country of ref document: PH

Ref document number: 10620759

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 9292003

Country of ref document: SK

Ref document number: 028038894

Country of ref document: CN

Ref document number: 2002560665

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2002247634

Country of ref document: AU

Ref document number: 1134/DELNP/2003

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 527148

Country of ref document: NZ

WWP Wipo information: published in national office

Ref document number: 1020037009470

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: PV2003-1900

Country of ref document: CZ

WWP Wipo information: published in national office

Ref document number: 2002716661

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 527148

Country of ref document: NZ

WWG Wipo information: grant in national office

Ref document number: 527148

Country of ref document: NZ

WWW Wipo information: withdrawn in national office

Ref document number: 2002716661

Country of ref document: EP